Brian Krzanich, who has been the CEO of the technology giant Intel (INTC) since 2003, has announced his resignation today from the group. The company’s board has named Chief Financial Officer Robert Swan as Interim CEO, effective immediately.
The chipmaker was informed recently that Krzanich had a mutual relationship with an Intel employee in the past. Intel had employed internal and external counsels to undertake a thorough investigation into the matter and it was confirmed that Krzanich had violated the company’s non-fraternization policy, following which the board has accepted his resignation.
Intel said that it has begun a search for a permanent CEO, including both internal and external candidates. The company also anticipates reporting record second quarter, with revenues expected to come in at about $16.9 billion and adjusted earnings of about $0.99 per share.
Krzanich first joined the company in 1982 as an engineer and served as Chief Operating Officer prior to being elevated to the position of Chief Executive Officer. As CEO, Krzanich tried to guide the chipmaker towards the technological advances of big data and self-driving cars. However, amidst these, he also had to deal with security fears concerning Intel’s chips in consumer devices.
With accelerating data-centric revenue, which lifted Intel’s first quarter results, the company is off to a vibrant start in the first half of the year and expects the full year to be another record year.
Related: Data-centric businesses lift Intel’s first quarter results
In late last 2017, Krzanich was under suspicion of insider trading, while he sold about $39 million worth of Intel’s shares after the company was informed of the Spectre (Spectre breaks the isolation between different applications) security flaws. Last year, Krzanich was criticized over his reaction to the Meltdown and Spectre flaws.
Related: Starbucks iconic leader Howard Schultz steps down
Intel’s stock dropped more than 1% in the initial trading hours today on the news of Krzanich’s exit from the company.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
